Domine Gomez, Manuel manuel.domine@uam.es
Publications
- Articles 38
- Books 1
- Book chapters 0
- Conferences 0
- Working papers 0
- Technical reports 0
- Research projects 0
- Supervised theses 0
- Patent or software license 0
Association of Performance Status and Pain in Metastatic Bone Pain Management in the Spanish Clinical Setting
- Dómine Gómez M
- Díaz Fernández N
- Cantos Sánchez de Ibargüen B
- Zugazabeitia Olabarría L
- Martínez Lozano J
- Poza de Celis R
- Trujillo Vílchez R
- Peláez Fernández I
- Capdevila Castillón J
- Traseira Lugilde S
- Esteban González E
Advances In Therapy (p. 136-147) - 1/1/2017
10.1007/s12325-016-0435-1 View at source
- ISSN 0741238X
Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: Results from the exploratory, controlled, randomized, international phase II IMPULSE study
- Thomas M, Ponce-Aix S, Navarro A, Riera-Knorrenschild J, Schmidt M, Wiegert E, Kapp K, Wittig B, Mauri C, Dómine Gómez M, Kollmeier J, Sadjadian P, Fröhling KP, Huber RM, Wolf M, IMPULSE study team
Annals Of Oncology (p. 2076-2084) - 1/10/2018
10.1093/annonc/mdy326 View at source
- ISSN 09237534
Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: A phase Ib/randomized phase II trial
- Weiss JM, Csoszi T, Maglakelidze M, Hoyer RJ, Beck JT, Domine Gomez M, Lowczak A, Aljumaily R, Rocha Lima CM, Boccia RV, Hanna W, Nikolinakos P, Chiu VK, Owonikoko TK, Schuster SR, Hussein MA, Richards DA, Sawrycki P, Bulat I, Hamm JT, Hart LL, Adler S, Antal JM, Lai AY, Sorrentino JA, Yang Z, Malik RK, Morris SR, Roberts PJ, Dragnev KH, G1T28-02 Study Group
Annals Of Oncology (p. 1613-1621) - 1/10/2019
10.1093/annonc/mdz278 View at source
- ISSN 09237534
A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial
- Soo RA, Han JY, Dafni U, Cho BC, Yeo CM, Nadal E, Carcereny E, de Castro J, Sala MA, Bernabé R, Coate L, Provencio Pulla M, Garcia Campelo R, Cuffe S, Hashemi SMS, Früh M, Massuti B, Garcia-Sanchez J, Dómine M, Majem M, Sanchez-Torres JM, Britschgi C, Pless M, Dimopoulou G, Roschitzki-Voser H, Ruepp B, Rosell R, Stahel RA, Peters S, ETOP 10-16 BOOSTER Collaborators
Annals Of Oncology (p. 181-192) - 1/2/2022
10.1016/j.annonc.2021.11.010 View at source
- ISSN 09237534
Galectin-1, a novel promising target for outcome prediction and treatment in SCLC
- Corral JM
- Puerto-Nevado LD
- Cedeño M
- Río-Vilariño A
- Mahillo-Fernández I
- Galeano C
- Baños N
- García-Foncillas J
- Dómine M
- Cebrián A
Biomedicine & Pharmacotherapy (p. 113987-113987) - 1/12/2022
- ISSN 07533322
- iMarina
Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics
- Provencio M
- Cobo M
- Rodriguez-Abreu D
- Calvo V
- Carcereny E
- Cantero A
- Bernabé R
- Benitez G
- Castro RL
- Massutí B
- del Barco E
- García Campelo R
- Guirado M
- Camps C
- Ortega AL
- González Larriba JL
- Sánchez A
- Casal J
- Sala MA
- Juan-Vidal O
- Bosch-Barrera J
- Oramas J
- Dómine M
- Trigo JM
- Blanco R
- Calzas J
- Morilla I
- Padilla A
- Pimentao J
- Sousa PA
- Torrente M
Bmc Cancer - 1/12/2022
10.1186/s12885-022-09830-8 View at source
- ISSN 14712407
Molecular Divergence upon EGFR-TKI Resistance Could Be Dependent on the Exon Location of the Original EGFR-Sensitizing Mutation
- Serna-Blasco R
- Sánchez-Herrero E
- Robado de Lope L
- Sanz-Moreno S
- Rodríguez-Festa A
- Ares-Trotta D
- Cruz-Bermúdez A
- Franco F
- Sánchez-Hernández A
- Campayo MdJ
- García-Girón C
- Dómine M
- Blasco A
- Sánchez JM
- Oramas J
- Bosch-Barrera J
- Sala MA
- Sereno M
- Romero A
- Provencio M
Cancers - 1/9/2022
10.3390/cancers14184446 View at source
- ISSN 20726694
SEOM clinical guidelines for the treatmentof small-cell lung cancer
- Ángel Artal Cortés
- Manuel Dómine Gómez
- A Font
- María Rosario García Campelo
- Manuel Cobo Dols
- Dolores Isla Casado
Clinical & Translational Oncology (p. 27-31) - 1/1/2010
- ISSN 1699048X
- iMarina
SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015
- María Rosario García Campelo
- R Bernabé
- Manuel Cobo Dols
- J Corral
- Juan Coves
- Manuel Dómine Gómez
- E Nadal
- Delvys Rodríguez Abreu
- Núria Viñolas Segarra
- Bartomeu Massuti Sureda
Clinical & Translational Oncology (p. 1020-1029) - 1/1/2015
- ISSN 1699048X
- iMarina
Long-term survival in advanced non-squamous NSCLC patients treated with first-line bevacizumab-based therapy
- De Castro, J.
- González-Larriba, J.L.
- Vázquez, S.
- Massutí, B.
- Sanchez-Torres, J.M.
- Dómine, M.
- Garrido, P.
- Calles, A.
- Artal, A.
- Collado, R.
- García, R.
- Sereno, M.
- Majem, M.
- Macías, J.A.
- Juan, O.
- Gómez-Codina, J.
- Hernández, B.
- Lázaro, M.
- Ortega, A.L.
- Cobo, M.
- Trigo, J.M.
- Carcereny, E.
- Rolfo, C.
- Macia, S.
- Muñoz, J.
- Diz, P.
- Méndez, M.
- Rosillo, F.
- Paz-Ares, L.
- Cardona, J.V.
- Isla, D.
Clinical & Translational Oncology (p. 219-226) - 1/2/2017
Editor: Springer-Verlag Italia s.r.l.
10.1007/s12094-016-1527-8 View at source
- ISSN 1699048X
- ISSN/ISBN 1699-3055
This researcher has no book chapters.
This researcher has no conferences.
This researcher has no working papers.
This researcher has no technical reports.
This researcher has no research projects.
This researcher has no supervised thesis.
This researcher has no patents or software licenses.
Researcher profiles
-
ORCID
-
Scopus Author ID
-
Dialnet id